A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

St Vincent's Hospital Sydney, Darlinghurst

St. Vincent's Hospital Melbourne, Fitzroy

Monash Health Clinical Trial Pharmacy department, Clayton

Icon Cancer Care South Brisbane, South Brisbane

Princess Alexandra Hospital, Woolloongabba

Royal Adelaide Hospital, Adelaide

The Perth Blood Institute, Nedlands

Royal Hobart Hospital, Hobart

New York Uni Medical Center, New York

Memorial Sloan Kettering Cancer Center at Westchester, Harrison

Memorial Sloan Kettering Cancer Center - Commack, Commack

University of Pennsylvania, Philadelphia

Clínica Universidad de Navarra, Pamplona

Complejo Asistencial Universitario de Salamanca, Salamanca

Universitatsklinikum Koln, Cologne

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz, Mainz

Universitätsklinikum Heidelberg, Heidelberg

MD Anderson Cancer Center, Houston

Rocky Mountain Cancer Center, Denver

Klinikum der Universität München, Campus Großhadern, München

Sansum Medical Clinic, Inc., Santa Barbara

Willamette Valley Cancer Insitute and Research Center, Springfield

Hospital Universitario La Paz, Madrid

University of California San Diego Moores Cancer Center, La Jolla

Yale University School Of Medicine, New Haven

Hackensack University Medical Center, Hackensack

Memorial Sloan Kettering Bergen, Montvale

Princess Margaret Hospital, Toronto

Jewish General Hospital, Montreal

Seoul National University Hospital, Seoul

Samsung Medical Center, Seoul

Hospital Universitario Vall d Hebron, Barcelona

Barts Cancer Institute, London

The Christie NHS Foundation Trust, Manchester

Royal Marsden Hospital;Institute of Cancer Research, Sutton